Compare Campbell Soup Co. (CPB) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Gilead Sciences, Inc. — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.78B), while Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 24.8× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | GILD | |
|---|---|---|
Market Cap | $6.78B | $168.35B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $155.80 |
52-Week Low | $20.00 | $110.56 |
Enterprise Value | $13.38B | $191.42B |
Dividend Yield | 6.87% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
